POESIT recommendations on management of body-identical hormones in menopausal symptoms.

Many women seek treatment to improve menopausal vasomotor symptoms (VMS). The selection of women most likely to benefit from menopause hormone therapy (MHT) is crucial in clinical practice. There is general agreement that women younger than 60 years or who initiate MHT within the first 10 years of menopause, with no contraindications, have greater benefits considering symptomatic relief and additional advantages.

Recommendations on the management of fragility fracture risk in women younger than 70 years.

The risk for fragility fracture represents a problem of enormous magnitude. It is estimated that only a small fraction of women with this risk take the benefit of preventive measures. The relationship between estrogen and bone mass is well known as they are the other factors related to the risk for fracture.

Menopause and aging: changes in the immune system--a review.

Background: The higher risk of women developing autoimmune diseases suggests that immune system is mediated by sex steroids.

Objective: To review the effects of aging and menopause in immune system.

Methods: A systematic review of in vitro, animal and human studies involving aging and menopause and immune system was carried out.

Changes in the immune system during menopause and aging.

The fact that gender influences the immune system has long been recognised. The higher risk of women developing autoimmune diseases suggests that these are somehow mediated by sex steroids, with estrogens as enhancers at least of the humoral immunity and androgens and progesterone as natural immune-suppressors. The concept of immunosenescence reflects changes in both cellular and humoral immune responses.